Congestive Heart Failure – Major World Markets, Volume I – Pharmaceutical Management

Table of Contents

TABLE OF CONTENTS

CHAPTER ONE: EXECUTIVE SUMMARY

• Background
• Scope and Methodology
• Size and Growth of Market
• Market Trends
• The Nature of the Industry
• The New Technologies

CHAPTER TWO: INTRODUCTION

• Background
• Pathophysiology
• Types of Heart Failure
• Left Ventricular (LV) Failure
• Right Ventricular (RV) Failure
• Systolic Dysfunction
• Diastolic Dysfunction
• High Output Failure
• Theories of Congestive Heart Failure
• Hemodynamic Response Theory
• Neurohormonal Response Theory
• Renal Response Theory
• Conditions Leading to Congestive Heart Failure
• Myocardial Infarction
• Hypertension
• Cardiomyopathy
• Atrial Fibrillation
• Other Risk Factors
• Diagnosis of Congestive Heart Failure
• Classification of Congestive Heart Failure Patients
  • Epidemiology
  • United States
  • Europe
  • Japan

CHAPTER THREE:TREATMENT OF CONGESTIVE HEART FAILURE

• Pharmacological Therapy
  • Overview
• Standard Pharmacological Therapy
  • ACE Inhibitors and Related Drugs
  • Angiotensin II Receptor Inhibitors (ARBs)
  • â-Blockers
  • Diuretics
  • Positive Inotropic Agents
  • Vasodilators
  • Aldosterone Blockers
  • Limitations of Pharmaceuticals
• Emerging Drugs to Treat Congestive Heart Failure

CHAPTER FOUR: CONGESTIVE HEART FAILURE PATIENT MANAGEMENT

• Guidelines for Management of Chronic Heart Failure
• Strategies to Maintain Quality Patient Care and Con`tain Costs
  • Patient Education Programs
  • Dedicated Multidisciplinary Congestive Heart Failure Clinics

CHAPTER FIVE: THE MARKET FOR CHF PHARMACEUTICALS

• Market Analysis
  • United States
  • Europe
  • Japan

CHAPTER SIX: COMPANY PROFILES

• Abbott Laboratories
• Actelion Pharmaceuticals US
• Aldagen
• Alexion Pharmaceuticals
• AstraZeneca LP
• Bayer Healthcare Pharmaceuticals (Bayer Schering Pharma)
• Bristol-Myers Squibb
• CardioVascular Biotherapeutics
• CoGenesys, Inc.
• Encysive Pharmaceuticals
• GlaxoSmithKline (US)
• Inotek Pharmaceuticals
• Mylan Pharmaceuticals
• Novartis Pharmaceutical Corp.
• Pfizer, Inc.
• Roche Pharmaceuticals
• Sanofi-Aventis (US)
• Scios, Inc.
• Vasogen, Inc.
• Zealand Pharma

CHAPTER SEVEN: CONCLUSIONS AND STRATEGIC IMPLICATIONS

• First Conclusion
• Second Conclusion
• Third Conclusion
• Fourth Conclusion
• Fifth Conclusion
• Sixth Conclusion
• Seventh Conclusion
• Eighth Conclusion

APPENDIX A: GLOSSARY

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

• Figure 1-1: Incidence of Congestive Heart Failure Cases in the Major World Healthcare Markets: 2007 – 2017
• Figure 1-2: Prevalence of Congestive Heart Failure Cases in the Major World Healthcare Markets: 2007 – 2017
• Table 1-1: Estimated Market Sizes for CHF Pharmaceuticals in the Major World Healthcare Markets: 2007 – 2017 (US$ Billions)
• Figure 1-3: Market Potential Trending and Composition for Congestive Heart Failure Therapeutics in the World’s Major Therapy Markets:2007 – 2017
• Figure 1-4: Composition of the Markets for Congestive Heart Failure Therapeutics by Product Classification: 2007 – 2017 Table 1-3: Examples of Companies Competitive in Congestive Heart Failure Therapeutics

CHAPTER TWO: INTRODUCTION

• Table 2-1: International Cardiovascular Disease (CVD) Statistics
• Table 2-2: United States CHF Statistics: 2004
• Table 2-3: CHF Data Sources
• Table 2-4: Common Contributors to Congestive Heart Failure
• Figure 2-1: Incidence and Prevalence of Congestive Heart Failure In the World’s Major Healthcare Markets: 2007 – 2017
• Figure 2-2: Incidence Rates of Congestive Heart Failure in the Major World Healthcare Markets: 200l – 2017
• Figure 2-3: Prevalence Rates of Congestive Heart Failure in the Major World Healthcare Markets: 2007 – 2017
• Figure 2-4: Percentage Breakdown of Deaths from Cardiovascular Diseases: 2003
• Table 2-5: Incidence and Prevalence of CHF in the United States: 2007 – 2017
• Figure 2-5: Incidence and Prevalence of CHF in the United States: 2007 – 2017
• Figure 2-6: The Distribution of Congestive Heart Failure In the Five Major European Healthcare Markets: 2007
• Table 2-6: Incidence and Prevalence of CHF in the Major Healthcare Markets of Europe: 2007 – 2017 (Thousands) Figure 2-7: Incidence and Prevalence of CHF in the Major Healthcare Markets of Europe: 2007 – 20017 (Thousands)
• Table 2-7: Incidence and Prevalence of CHF in Japan: 2007 – 2017
• Figure 2-8: Incidence and Prevalence of CHF in Japan: 2007 – 20017

CHAPTER THREE: TREATMENT OF CONGESTIVE HEART FAILURE

• Table 3-1: Therapeutic Strategies for Symptomatic Congestive Heart Failure
• Table 3-2: Pharmacological Response to the Pathophysiology of Cardiac Performance
• Table 3-3: Common ACE Inhibitors Recommended for the Treatment of CHF
• Table 3-4: Common Angiotensin II Receptor Antagonists Recommended for the Treatment of CHF
• Table 3-5: Common â-Receptor Antagonists Recommended for the Treatment of CHF
• Table 3-6: Common Diuretics Recommended for the Treatment of CHF
• Table 3-7: Common Inotropic Drugs Available for the Treatment of CHF
• Table 3-8: Common Vasodilators Available for the Treatment of CHF
• Table 3-9: Common Aldosterone Blocking Drugs Recommended for the Treatment of CHF
• Table 3-10: New Drugs in Development for the Treatment of CHF

CHAPTER FOUR: CONGESTIVE HEART FAILURE PATIENT MANAGEMENT

• Figure 4-1: ACC/AHA Guideline Summary for Recommended Therapy of Congestive Heart Failure by Stage of the Disease
• Table 4-1: ACC/AHA Staging of Congestive Heart Failure
• Table 4-2: 2005 ACC/AHA Guidelines for Evaluation and Therapy for Congestive Heart Failure

CHAPTER FIVE: THE MARKET FOR CHF PHARMACEUTICALS

• Table 5-1: Estimated Market Potential for CHF Pharmaceuticals in the Major World Healthcare Markets: 2007 – 2017
• Figure 5-1: Trending in the Estimated Market Potential for CHF Pharmaceuticals in the Major World Healthcare Markets: 2007 – 2017
• Figure 5-2: Distribution of the Estimated Market Potential for CHF Pharmaceuticals in the Major World Healthcare Markets: 2007 – 2017
• Table 5-2: Estimated Market Potential for CHF Pharmaceuticals in the United States: 2007 – 2017 ($Billions)
• Figure 5-3: Trending in the Estimated Market Potential for CHF Pharmaceuticals in the United States: 2007 – 2017
• Figure 5-4: Distribution of the Estimated Market Potential by Segments for CHF Pharmaceuticals in the United States: 2007 – 2017
• Table 5-3: Estimated Market Potential for CHF Pharmaceuticals in the Major European Markets: 2007 – 2017
• Figure 5-5: Trending in the Estimated Market Potential for CHF Pharmaceuticals in the Major European Markets: 2007 – 2017
• Figure 5-6: Distribution of the Estimated Market Potential by Segments for CHF Pharmaceuticals in the Major European Markets: 2007 – 2017
• Table 5-4: Estimated Market Potential for CHF Pharmaceuticals in the Japanese Market: 2007 – 2017
• Figure 5-7: Trending in the Estimated Market Potential for CHF Pharmaceuticals in the Japanese Market: 2007 – 2017
• Figure 5-8: Distribution of the Estimated Market Potential by Segments for CHF Pharmaceuticals in the Japanese Market: 2007 – 2017